Novartis bets on experimental cancer treatment from US firm
Keystone / Georgios Kefalas
The Swiss pharma giant has made an offer to buy the rights to a tumor inhibiting treatment from Clovis Oncology in Colorado, which has filed for bankruptcy protection.
This content was published on
1 minute
Keystone-SDA/ac
Português
pt
Novartis aposta em tratamento experimental do câncer de empresa americana
Novartis has committed to pay $50 million (just under CHF47 million) upfront for all rights to the experimental cancer treatment. In addition, the Basel-based company has agreed to pay out up to an additional $333.75 million upon the successful reaching of development and regulatory milestones and $297 million in later sales milestones.
The experimental treatment and imaging agent known as FAP-2286 is in a phase I/II study, called Lumière, for its ability to bind to a fibroblast activating protein (FAP), Clovis said in a statement on Monday. It is the first peptide-targeted radionuclide therapy (PTRT) and imaging agent targeting FAP to enter clinical development.
The acquisition by Novartis is what is known as a “stalking horse purchase”. Clovis intends to submit the Novartis offer to other potential buyers in the hope of attracting competing proposals. These will be reviewed with advisers in a proceeding supervised by the U.S. Bankruptcy Court for the District of Delaware.
How is your country dealing with the return of stolen artifacts?
Western nations like Switzerland often have to deal with the process of recovering or returning looted artifacts which have been illegally imported. What’s the situation like in your country?
What do you think Switzerland’s Alain Berset can bring to the Council of Europe?
The former interior minister is to become the first Swiss Secretary General of the Council of Europe – which issues should his five-year term focus on?
Algerian to face trial in Switzerland for ties to Islamic State
This content was published on
A 51-year-old Algerian man has been charged by the Swiss Federal Prosecutor's Office for involvement in the banned terrorist group.
Sylvain Saudan, ‘skier of the impossible’, dies aged 87
This content was published on
The Swiss father of extreme skiing pioneered descents from the Alps to the Himalayas – and became the sport’s first star.
Hayek family buys additional Swatch shares for nearly CHF11 million
This content was published on
Following the acquisition of registered shares worth over CHF20.6 million on Monday, the Hayek family made another purchase on Tuesday.
Suicide capsule to be used in Switzerland this year, says euthanasia organisation
This content was published on
The organisation “The Last Resort” has confirmed that the suicide capsule Sarco is to be used in Switzerland. This should happen this year, it said.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.